Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
Rheumatology
•
Hematology
•
Pediatric Hematology
•
Cyclophosphamide
•
General Rheumatology
•
Neutropenia
When would you consider using G-CSF in patients with rheumatic disease who have received cyclophosphamide?
Related Questions
How do you approach dosing of anakinra in MAS?
What is your approach to further work-up and management of neutropenia in patients with SLE/RA overlap?
What is your surveillance protocol for patients with common variable immunodeficiency receiving chronic IVIG therapy?
Is there a concern for the potential of future congenital malformations in offspring when preservation of eggs and sperm is done AFTER cyclophosphamide treatment given that it is an alkylating agent?
How do you approach low to moderate titer of APLS when working up unprovoked DVT if it is persistent on repeat testing?
How do you approach diagnosis and treatment of HLH/MAS following CAR T-cell therapy?
Should testing for genetic causes of HLH be performed in all patients with MAS or secondary HLH regardless of the patient's age?
In the setting of secondary HLH associated with initial diagnosis of lymphoma, would you adjust steroid dose and type to account for differences in HLH and lymphoma treatment protocols?
How do you approach evaluation and management of arthralgia in a patient after CAR-T cell therapy?
What is your approach to management of chronic neutropenia in a patient with Sjogren’s who was recently diagnosed with metastatic endometrial cancer and plans to start chemotherapy?